FDA approves UCB’s Cimzia in plaque psoriasisThe US FDA has approved a label extension for UCB’s Cimzia (certolizumab pegol) for adults with moderate-to-severe plaque psoriasis Share XFDA approves UCB’s Cimzia in plaque psoriasishttps://pharmaphorum.com/news/fda-ucbs-cimzia-plaque-psoriasis/